> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Advisors Support Victoza sNDA
- URL: https://www.fdaweb.com/fda-advisors-support-victoza-snda/
- Published: 2017-06-21T12:00:00.000Z
- Updated: 2026-09-14T22:30:35.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138990

Members of the FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 19-0 that the results of the LEADER trial establish that use of Novo Nordisk’s Victoza (liraglutide) in patients with Type 2 diabetes is not associated with excess cardiovascular risk. The 10/2016 sNDA requested inclusion of the LEADER cardiovascular outcomes data in the Victoza label.

The committee also voted 17-2 that the trial provides the substantial evidence needed to establish that Victoza 1.8 mg injection reduces cardiovascular risk in patients with Type 2 diabetes.